Previous 10 | Next 10 |
2024-05-04 03:39:35 ET Summary Schwab U.S. Dividend Equity ETF is a popular choice for income-oriented investors, diversification and a defensive approach. SCHD offers exposure to dividend-paying firms with healthy balance sheets, offering investors resilience in turbulent times. ...
2024-05-03 18:15:34 ET Amgen (NASDAQ: AMGN) released its latest set of quarterly results after market hours Thursday, and investors rewarded the pharmaceutical company the following day with a lift to its share price. The stock rose by almost 12% on Friday, but much of that was due ...
2024-05-03 13:45:00 ET Summary Amgen released its Q1'24 earnings earlier today with revenues increasing 22% YoY to $7.45bn, with non-GAAP net income of $2.14bn. Non-GAAP EPS fell by 1% YoY to $3.96 per share, and GAAP EPS to $(0.21) owing to underlying Beigene holding and costs re...
2024-05-03 12:29:38 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Amgen stock rallies 13% on GLP-1 weight-loss drug update ...
Stocks jumped sharply Friday after a softer-than-expected April jobs report boosted hopes that the Federal Reserve could start cutting interest rates soon. The Dow Jones Industrials popped 524,51 points, or 1.4%, to begin Friday at 38,750.17. The S&P 500 galloped 62.12 points, or 1.2%...
Amgen Inc. (NASDAQ: AMGN) is one of today's top gainers. The company's shares have moved 12.15% on the day to $312.21. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, ...
2024-05-03 10:28:54 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Biggest stock movers today: WOW, AAPL, SQ, and more Amge...
2024-05-03 06:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for AMGN on May 3, 2024 04:38AM ET. The previous analyst recommendation was Underweight. AMGN was trading at $278.39 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-03 05:14:40 ET More on related stocks: Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Apple Inc. (AAPL) Q2 2024 Earnings Call Transcript Cloudflare, Inc. (NET) Q1 2024 Earnings Call Transcript Apple in charts: iPhone revenue slumps Y/Y; services ...
2024-05-02 21:12:05 ET Amgen, Inc. (AMGN) Q1 2024 Earnings Conference Call May 02, 2024, 16:30 ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President James Bradner - EVP, Research and Development & Chief Scientific Offic...
News, Short Squeeze, Breakout and More Instantly...
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 8.86%....
2024-05-31 13:22:01 ET Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts project significant growth in this sector, with Amgen among key players like Novo Nordisk and Eli Lilly. The U.S. FDA has approved Amge...
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDA...